Tumor-penetrating therapy for β5 integrin-rich pancreas cancer

The iRGD tumor-penetrating peptide can achieve tumor specific drug delivery but whether and how it can penetrate into desmoplastic tumors is unknown. Here, the authors show that β5 integrin expression on tumor cells, mediated by CAFs-derived TGF-β, is required for iRGD penetration into the desmoplas...

Full description

Bibliographic Details
Main Authors:	Tatiana Hurtado de Mendoza, Evangeline S. Mose, Gregory P. Botta, Gary B. Braun, Venkata R. Kotamraju, Randall P. French, Kodai Suzuki, Norio Miyamura, Tambet Teesalu, Erkki Ruoslahti, Andrew M. Lowy, Kazuki N. Sugahara
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-03-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-021-21858-1

id	doaj-80f9f85745054067b544050e7b18b670
record_format	Article
spelling	doaj-80f9f85745054067b544050e7b18b6702021-03-11T11:33:46ZengNature Publishing GroupNature Communications2041-17232021-03-0112111310.1038/s41467-021-21858-1Tumor-penetrating therapy for β5 integrin-rich pancreas cancerTatiana Hurtado de Mendoza0Evangeline S. Mose1Gregory P. Botta2Gary B. Braun3Venkata R. Kotamraju4Randall P. French5Kodai Suzuki6Norio Miyamura7Tambet Teesalu8Erkki Ruoslahti9Andrew M. Lowy10Kazuki N. Sugahara11Cancer Research Center, Sanford-Burnham-Prebys Medical Discovery InstituteDepartment of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of CaliforniaCancer Research Center, Sanford-Burnham-Prebys Medical Discovery InstituteCancer Research Center, Sanford-Burnham-Prebys Medical Discovery InstituteCancer Research Center, Sanford-Burnham-Prebys Medical Discovery InstituteDepartment of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of CaliforniaDepartment of Surgery, Columbia University Vagelos College of Physicians and SurgeonsDepartment of Surgery, Columbia University Vagelos College of Physicians and SurgeonsCancer Research Center, Sanford-Burnham-Prebys Medical Discovery InstituteCancer Research Center, Sanford-Burnham-Prebys Medical Discovery InstituteDepartment of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of CaliforniaCancer Research Center, Sanford-Burnham-Prebys Medical Discovery InstituteThe iRGD tumor-penetrating peptide can achieve tumor specific drug delivery but whether and how it can penetrate into desmoplastic tumors is unknown. Here, the authors show that β5 integrin expression on tumor cells, mediated by CAFs-derived TGF-β, is required for iRGD penetration into the desmoplastic PDAC microenvironment and that iRGD-based combination therapy is effective in PDAC mouse models.https://doi.org/10.1038/s41467-021-21858-1
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Tatiana Hurtado de Mendoza Evangeline S. Mose Gregory P. Botta Gary B. Braun Venkata R. Kotamraju Randall P. French Kodai Suzuki Norio Miyamura Tambet Teesalu Erkki Ruoslahti Andrew M. Lowy Kazuki N. Sugahara
spellingShingle	Tatiana Hurtado de Mendoza Evangeline S. Mose Gregory P. Botta Gary B. Braun Venkata R. Kotamraju Randall P. French Kodai Suzuki Norio Miyamura Tambet Teesalu Erkki Ruoslahti Andrew M. Lowy Kazuki N. Sugahara Tumor-penetrating therapy for β5 integrin-rich pancreas cancer Nature Communications
author_facet	Tatiana Hurtado de Mendoza Evangeline S. Mose Gregory P. Botta Gary B. Braun Venkata R. Kotamraju Randall P. French Kodai Suzuki Norio Miyamura Tambet Teesalu Erkki Ruoslahti Andrew M. Lowy Kazuki N. Sugahara
author_sort	Tatiana Hurtado de Mendoza
title	Tumor-penetrating therapy for β5 integrin-rich pancreas cancer
title_short	Tumor-penetrating therapy for β5 integrin-rich pancreas cancer
title_full	Tumor-penetrating therapy for β5 integrin-rich pancreas cancer
title_fullStr	Tumor-penetrating therapy for β5 integrin-rich pancreas cancer
title_full_unstemmed	Tumor-penetrating therapy for β5 integrin-rich pancreas cancer
title_sort	tumor-penetrating therapy for β5 integrin-rich pancreas cancer
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2021-03-01
description	The iRGD tumor-penetrating peptide can achieve tumor specific drug delivery but whether and how it can penetrate into desmoplastic tumors is unknown. Here, the authors show that β5 integrin expression on tumor cells, mediated by CAFs-derived TGF-β, is required for iRGD penetration into the desmoplastic PDAC microenvironment and that iRGD-based combination therapy is effective in PDAC mouse models.
url	https://doi.org/10.1038/s41467-021-21858-1
work_keys_str_mv	AT tatianahurtadodemendoza tumorpenetratingtherapyforb5integrinrichpancreascancer AT evangelinesmose tumorpenetratingtherapyforb5integrinrichpancreascancer AT gregorypbotta tumorpenetratingtherapyforb5integrinrichpancreascancer AT garybbraun tumorpenetratingtherapyforb5integrinrichpancreascancer AT venkatarkotamraju tumorpenetratingtherapyforb5integrinrichpancreascancer AT randallpfrench tumorpenetratingtherapyforb5integrinrichpancreascancer AT kodaisuzuki tumorpenetratingtherapyforb5integrinrichpancreascancer AT noriomiyamura tumorpenetratingtherapyforb5integrinrichpancreascancer AT tambetteesalu tumorpenetratingtherapyforb5integrinrichpancreascancer AT erkkiruoslahti tumorpenetratingtherapyforb5integrinrichpancreascancer AT andrewmlowy tumorpenetratingtherapyforb5integrinrichpancreascancer AT kazukinsugahara tumorpenetratingtherapyforb5integrinrichpancreascancer
_version_	1724225402780516352

Tumor-penetrating therapy for β5 integrin-rich pancreas cancer

Similar Items